281 related articles for article (PubMed ID: 22059994)
1. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
Namboodiri AM; Pandey JP
Clin Exp Immunol; 2011 Dec; 166(3):361-5. PubMed ID: 22059994
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin GM and FcγRIIIa genotypes influence cytotoxicity of neuroblastoma cells.
Pandey JP; Namboodiri AM
J Neuroimmunol; 2014 May; 270(1-2):95-7. PubMed ID: 24662005
[TBL] [Abstract][Full Text] [Related]
3. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
4. FcγR Binding and ADCC Activity of Human IgG Allotypes.
de Taeye SW; Bentlage AEH; Mebius MM; Meesters JI; Lissenberg-Thunnissen S; Falck D; Sénard T; Salehi N; Wuhrer M; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2020; 11():740. PubMed ID: 32435243
[TBL] [Abstract][Full Text] [Related]
5. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
6. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
[TBL] [Abstract][Full Text] [Related]
7. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
9. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
10. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
11. Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer.
Pandey JP; Namboodiri AM; Kistner-Griffin E; Iwasaki M; Kasuga Y; Hamada GS; Tsugane S
Clin Exp Immunol; 2013 Mar; 171(3):273-7. PubMed ID: 23379433
[TBL] [Abstract][Full Text] [Related]
12. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.
Pandey JP; Namboodiri AM
Oncoimmunology; 2014 Jan; 3(1):e27317. PubMed ID: 24701371
[TBL] [Abstract][Full Text] [Related]
14. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
[TBL] [Abstract][Full Text] [Related]
15. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
16. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
18. NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation.
Moraru M; Black LE; Muntasell A; Portero F; López-Botet M; Reyburn HT; Pandey JP; Vilches C
J Immunol; 2015 Aug; 195(4):1676-84. PubMed ID: 26179905
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
20. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
